Sulforaphane epigenetically enhances neuronal BDNF expression and TrkB signaling pathways.
Level 5 - mechanism / opinion, no new human data
Preclinical in vitro and animal model study without human clinical data
PubMed 27735126 · doi:10.1002/mnfr.201600194
What was done
Researchers evaluated the neuroprotective mechanisms of sulforaphane using mouse primary cortical neurons and a triple-transgenic mouse model of Alzheimer's disease (3 × Tg-AD). They measured BDNF expression, synaptic and neuronal structural markers (MAP2, synaptophysin, PSD-95), TrkB downstream signaling proteins (CREB, CaMKII, ERK, Akt), histone acetylation (H3 and H4), HDAC activity, HDAC2 levels, and histone acetylation at BDNF promoters via chromatin immunoprecipitation.
What was found
The abstract reports no numerical values, effect sizes, or statistical metrics. Qualitatively, sulforaphane increased BDNF expression, synaptic/neuronal markers (MAP2, synaptophysin, PSD-95), and TrkB signaling pathway intermediates (CREB, CaMKII, ERK, Akt) in both primary neurons and 3 × Tg-AD mice. In cortical neurons, sulforaphane inhibited HDAC activity, reduced HDAC2 expression, and increased global and BDNF promoter-specific H3 and H4 acetylation.
Why it matters
This study outlines a potential epigenetic mechanism—HDAC inhibition and BDNF promoter hyperacetylation—by which sulforaphane may support neuronal and synaptic integrity in neurodegenerative models.
Limits
The study is restricted to in vitro cell cultures and an animal model, providing no human clinical data. The abstract omits sample sizes, dosages, exposure durations, quantitative effect sizes, and behavioral or cognitive outcome measures.
Cited by
- supports Sulforaphane upregulates brain-derived neurotrophic factor (BDNF).